Dpp4 inhibition as a therapeutic strategy in cardiometabolic disease: Incretin-dependent and -independent function

International Journal of Cardiology

Volumn 197, Issue , 2015, Pages 170-179

  Gong, Quan ^a   Rajagopalan, Sanjay ^b   Zhong, Jixin ^a,b  

^a YANGTZE UNIVERSITY   (China)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiometabolic disease; Diabetes; DPP4; GLP 1; Incretin

Indexed keywords

ALOGLIPTIN; ANAGLIPTIN; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLITAZONE DERIVATIVE; INCRETIN; INSULIN; LINAGLIPTIN; METFORMIN; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; TENELIGLIPTIN; VILDAGLIPTIN; DPP4 PROTEIN, HUMAN;

ARTICLE; CARDIOMETABOLIC DISEASE; CARDIOVASCULAR DISEASE; CATALYSIS; CELLULAR DISTRIBUTION; CIRCULATION; DIABETES MELLITUS; DISEASE SEVERITY; DRUG MECHANISM; ENZYME INHIBITION; ENZYME LOCALIZATION; HEADACHE; HUMAN; INSULIN RELEASE; METABOLIC DISORDER; MOLECULAR MECHANICS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHINOPHARYNGITIS; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; CARDIOVASCULAR DISEASES; DRUG EFFECTS; METABOLISM;

CARDIOVASCULAR DISEASES; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; HUMANS; INCRETINS;

EID: 84938541530     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2015.06.076     Document Type: Article

References (163)

1. A.J. Kwok, M. Mashar, K. Khavandi, and I. Sabir DPP-IV inhibitors: beyond glycaemic control? Trends Cardiovasc. Med. 24 2014 157 164
2. M. Sauve, K. Ban, M.A. Momen, Y.Q. Zhou, R.M. Henkelman, M. Husain, and et al. Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice Diabetes 59 2010 1063 1073
3. T. Shigeta, M. Aoyama, Y.K. Bando, A. Monji, T. Mitsui, M. Takatsu, and et al. Dipeptidyl peptidase-4 modulates left ventricular dysfunction in chronic heart failure via angiogenesis-dependent and -independent actions Circulation 126 2012 1838 1851
4. H.R. Patil, F.J. Al Badarin, H.A. Al Shami, S.K. Bhatti, C.J. Lavie, D.S. Bell, and et al. Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus Am. J. Cardiol. 110 2012 826 833
5. P.A. Read, F.Z. Khan, P.M. Heck, S.P. Hoole, and D.P. Dutka DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease Circ. Cardiovasc. Imaging 3 2010 195 201
6. A.J. Scheen Cardiovascular effects of gliptins Nat. Rev. Cardiol. 10 2013 73 84
7. B.M. Scirica, D.L. Bhatt, E. Braunwald, P.G. Steg, J. Davidson, B. Hirshberg, and et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus N. Engl. J. Med. 369 2013 1317 1326
8. W.B. White, C.P. Cannon, S.R. Heller, S.E. Nissen, R.M. Bergenstal, G.L. Bakris, and et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes N. Engl. J. Med. 369 2013 1327 1335
9. J. Zhong, X. Rao, and S. Rajagopalan An emerging role of dipeptidyl peptidase 4 (DPP4) beyond glucose control: potential implications in cardiovascular disease Atherosclerosis 226 2013 305 314
10. C.A. Abbott, D.M. Yu, E. Woollatt, G.R. Sutherland, G.W. McCaughan, and M.D. Gorrell Cloning, expression and chromosomal localization of a novel human dipeptidyl peptidase (DPP) IV homolog, DPP8 Eur. J. Biochem. 267 2000 6140 6150
11. V.K. Hopsu-Havu, and G.G. Glenner A new dipeptide naphthylamidase hydrolyzing glycyl-prolyl-beta-naphthylamide Histochem. Histochem. Histochim. 7 1966 197 201
12. V.K. Hopsu-Havu, and S.R. Sarimo Purification and characterization of an aminopeptidase hydrolyzing glycyl-proline-naphthylamide Hoppe-Seyler's Z. Physiol. Chem. 348 1967 1540 1550
13. V.K. Hopsu-Havu, P. Rintola, and G.G. Glenner A hog kidney aminopeptidase liberating N-terminal dipeptides. Partial purification and characteristics Acta Chem. Scand. 22 1968 299 308
14. D.J. Drucker Enhancing incretin action for the treatment of type 2 diabetes Diabetes Care 26 2003 2929 2940
15. C.A. Abbott, G.W. McCaughan, M.T. Levy, W.B. Church, and M.D. Gorrell Binding to human dipeptidyl peptidase IV by adenosine deaminase and antibodies that inhibit ligand binding involves overlapping, discontinuous sites on a predicted beta propeller domain Eur. J. Biochem. 266 1999 798 810
16. E. Richard, F.X. Arredondo-Vega, I. Santisteban, S.J. Kelly, D.D. Patel, and M.S. Hershfield The binding site of human adenosine deaminase for CD26/Dipeptidyl peptidase IV: the Arg142Gln mutation impairs binding to cd26 but does not cause immune deficiency J. Exp. Med. 192 2000 1223 1236
17. S. Iwaki-Egawa, Y. Watanabe, Y. Kikuya, and Y. Fujimoto Dipeptidyl peptidase IV from human serum: purification, characterization, and N-terminal amino acid sequence J. Biochem. 124 1998 428 433
18. G.W. McCaughan, J.E. Wickson, P.F. Creswick, and M.D. Gorrell Identification of the bile canalicular cell surface molecule GP110 as the ectopeptidase dipeptidyl peptidase IV: an analysis by tissue distribution, purification and N-terminal amino acid sequence Hepatology 11 1990 534 544
19. H.B. Rasmussen, S. Branner, F.C. Wiberg, and N. Wagtmann Crystal structure of human dipeptidyl peptidase IV/CD26 in complex with a substrate analog Nat. Struct. Biol. 10 2003 19 25
20. M.D. Gorrell Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders Clin. Sci. (Lond.) 108 2005 277 292
21. K. Ajami, C.A. Abbott, M. Obradovic, V. Gysbers, T. Kahne, G.W. McCaughan, and et al. Structural requirements for catalysis, expression, and dimerization in the CD26/DPIV gene family Biochemistry 42 2003 694 701
22. F. David, A.M. Bernard, M. Pierres, and D. Marguet Identification of serine 624, aspartic acid 702, and histidine 734 as the catalytic triad residues of mouse dipeptidyl-peptidase IV (CD26). A member of a novel family of nonclassical serine hydrolases J. Biol. Chem. 268 1993 17247 17252
23. J. Dobers, M. Zimmermann-Kordmann, M. Leddermann, T. Schewe, W. Reutter, and H. Fan Expression, purification, and characterization of human dipeptidyl peptidase IV/CD26 in Sf9 insect cells Protein Expr. Purif. 25 2002 527 532
24. B. Fleischer CD26: a surface protease involved in T-cell activation Immunol. Today 15 1994 180 184
25. M. Engel, T. Hoffmann, L. Wagner, M. Wermann, U. Heiser, R. Kiefersauer, and et al. The crystal structure of dipeptidyl peptidase IV (CD26) reveals its functional regulation and enzymatic mechanism Proc. Natl. Acad. Sci. U. S. A. 100 2003 5063 5068
26. S. Mentzel, H.B. Dijkman, J.P. Van Son, R.A. Koene, and K.J. Assmann Organ distribution of aminopeptidase A and dipeptidyl peptidase IV in normal mice J. Histochem. Cytochem. Off. J. Histochem. Soc. 44 1996 445 461
27. J. Zhong, X. Rao, J. Deiuliis, Z. Braunstein, V. Narula, J. Hazey, and et al. A potential role for dendritic cell/macrophage-expressing DPP4 in obesity-induced visceral inflammation Diabetes 62 2013 149 157
28. J.S. Duke-Cohan, C. Morimoto, J.A. Rocker, and S.F. Schlossman Serum high molecular weight dipeptidyl peptidase IV (CD26) is similar to a novel antigen DPPT-L released from activated T cells J. Immunol. 156 1996 1714 1721
29. A.M. Lambeir, J.F. Diaz Pereira, P. Chacon, G. Vermeulen, K. Heremans, B. Devreese, and et al. A prediction of DPP IV/CD26 domain structure from a physico-chemical investigation of dipeptidyl peptidase IV (CD26) from human seminal plasma Biochim. Biophys. Acta 1340 1997 215 226
30. D. Lamers, S. Famulla, N. Wronkowitz, S. Hartwig, S. Lehr, D.M. Ouwens, and et al. Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome Diabetes 60 2011 1917 1925
31. Z. Wang, C. Grigo, J. Steinbeck, S. von Horsten, K. Amann, and C. Daniel Soluble DPP4 originates in part from bone marrow cells and not from the kidney Peptides 57 2014 109 117
32. T. Andrieu, V. Thibault, I. Malet, J. Laporte, B. Bauvois, H. Agut, and et al. Similar increased serum dipeptidyl peptidase IV activity in chronic hepatitis C and other viral infections J. Clin. Virol. Off. Publ. Pan Am. Soc. Clin. Virol. 27 2003 59 68
33. G. Grondin, N.M. Hooper, and D. LeBel Specific localization of membrane dipeptidase and dipeptidyl peptidase IV in secretion granules of two different pancreatic islet cells J. Histochem. Cytochem. Off. J. Histochem. Soc. 47 1999 489 498
34. N.J. Topham, and E.W. Hewitt Natural killer cell cytotoxicity: how do they pull the trigger? Immunology 128 2009 7 15
35. J.E. Park, M.C. Lenter, R.N. Zimmermann, P. Garin-Chesa, L.J. Old, and W.J. Rettig Fibroblast activation protein, a dual specificity serine protease expressed in reactive human tumor stromal fibroblasts J. Biol. Chem. 274 1999 36505 36512
36. J. Stremenova, V. Mares, V. Lisa, M. Hilser, E. Krepela, Z. Vanickova, and et al. Expression of dipeptidyl peptidase-IV activity and/or structure homologs in human meningiomas Int. J. Oncol. 36 2010 351 358
37. A.M. Santos, J. Jung, N. Aziz, J.L. Kissil, and E. Pure Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice J. Clin. Invest. 119 2009 3613 3625
38. C.E. Brokopp, R. Schoenauer, P. Richards, S. Bauer, C. Lohmann, M.Y. Emmert, and et al. Fibroblast activation protein is induced by inflammation and degrades type I collagen in thin-cap fibroatheromata Eur. Heart J. 32 2011 2713 2722
39. J. Tillmanns, C. Widera, Y. Habbaba, P. Galuppo, T. Kempf, K.C. Wollert, and et al. Circulating concentrations of fibroblast activation protein alpha in apparently healthy individuals and patients with acute coronary syndrome as assessed by sandwich ELISA Int. J. Cardiol. 168 2013 3926 3931
40. M.N. Pangalos, J.M. Neefs, M. Somers, P. Verhasselt, M. Bekkers, L. van der Helm, and et al. Isolation and expression of novel human glutamate carboxypeptidases with N-acetylated alpha-linked acidic dipeptidase and dipeptidyl peptidase IV activity J. Biol. Chem. 274 1999 8470 8483
41. D. Marguet, L. Baggio, T. Kobayashi, A.M. Bernard, M. Pierres, P.F. Nielsen, and et al. Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26 Proc. Natl. Acad. Sci. U. S. A. 97 2000 6874 6879
42. S.L. Conarello, Z. Li, J. Ronan, R.S. Roy, L. Zhu, G. Jiang, and et al. Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance Proc. Natl. Acad. Sci. U. S. A. 100 2003 6825 6830
43. K. Augustyns, G. Bal, G. Thonus, A. Belyaev, X.M. Zhang, W. Bollaert, and et al. The unique properties of dipeptidyl-peptidase IV (DPP IV/CD26) and the therapeutic potential of DPP IV inhibitors Curr. Med. Chem. 6 1999 311 327
44. C.H. Wilson, D. Indarto, A. Doucet, L.D. Pogson, M.R. Pitman, K. McNicholas, and et al. Identifying natural substrates for dipeptidyl peptidases 8 and 9 using terminal amine isotopic labeling of substrates (TAILS) reveals in vivo roles in cellular homeostasis and energy metabolism J. Biol. Chem. 288 2013 13936 13949
45. L. Pala, E. Mannucci, A. Pezzatini, S. Ciani, J. Sardi, L. Raimondi, and et al. Dipeptidyl peptidase-IV expression and activity in human glomerular endothelial cells Biochem. Biophys. Res. Commun. 310 2003 28 31
46. D.M. Yu, X.M. Wang, G.W. McCaughan, and M.D. Gorrell Extraenzymatic functions of the dipeptidyl peptidase IV-related proteins DP8 and DP9 in cell adhesion, migration and apoptosis FEBS J. 273 2006 2447 2460
47. E. Mannucci, L. Pala, S. Ciani, G. Bardini, A. Pezzatini, I. Sposato, and et al. Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus Diabetologia 48 2005 1168 1172
48. J. Ryskjaer, C.F. Deacon, R.D. Carr, T. Krarup, S. Madsbad, J. Holst, and et al. Plasma dipeptidyl peptidase-IV activity in patients with type-2 diabetes mellitus correlates positively with HbAlc levels, but is not acutely affected by food intake Eur. J. Endocrinol. 155 2006 485 493
49. R. Lugari, A. Dei Cas, D. Ugolotti, A.L. Barilli, C. Camellini, G.C. Ganzerla, and et al. Glucagon-like peptide 1 (GLP-1) secretion and plasma dipeptidyl peptidase IV (DPP-IV) activity in morbidly obese patients undergoing biliopancreatic diversion Horm. Metab. Res. 36 2004 111 115
50. S.A. Lee, Y.R. Kim, E.J. Yang, E.J. Kwon, S.H. Kim, S.H. Kang, and et al. CD26/DPP4 levels in peripheral blood and T cells in patients with type 2 diabetes mellitus J. Clin. Endocrinol. Metab. 98 2013 2553 2561
51. A.M. McKillop, N.A. Duffy, J.R. Lindsay, F.P. O'Harte, P.M. Bell, and P.R. Flatt Decreased dipeptidyl peptidase-IV activity and glucagon-like peptide-1(7-36)amide degradation in type 2 diabetic subjects Diabetes Res. Clin. Pract. 79 2008 79 85
52. J.M. Lenhard, D.K. Croom, and D.T. Minnick Reduced serum dipeptidyl peptidase-IV after metformin and pioglitazone treatments Biochem. Biophys. Res. Commun. 324 2004 92 97
53. J.R. Lindsay, N.A. Duffy, A.M. McKillop, J. Ardill, F.P. O'Harte, P.R. Flatt, and et al. Inhibition of dipeptidyl peptidase IV activity by oral metformin in type 2 diabetes Diabet. Med. 22 2005 654 657
54. B.D. Green, N. Irwin, N.A. Duffy, V.A. Gault, F.P. O'Harte, and P.R. Flatt Inhibition of dipeptidyl peptidase-IV activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1 Eur. J. Pharmacol. 547 2006 192 199
55. M. Miyazaki, M. Kato, K. Tanaka, M. Tanaka, M. Kohjima, K. Nakamura, and et al. Increased hepatic expression of dipeptidyl peptidase-4 in non-alcoholic fatty liver disease and its association with insulin resistance and glucose metabolism Mol. Med. Rep. 5 2012 729 733
56. M. Hildebrandt, W. Reutter, P. Arck, M. Rose, and B.F. Klapp A guardian angel: the involvement of dipeptidyl peptidase IV in psychoneuroendocrine function, nutrition and immune defence Clin. Sci. (Lond.) 99 2000 93 104
57. M. Kamori, M. Hagihara, T. Nagatsu, H. Iwata, and T. Miura Activities of dipeptidyl peptidase II, dipeptidyl peptidase IV, prolyl endopeptidase, and collagenase-like peptidase in synovial membrane from patients with rheumatoid arthritis and osteoarthritis Biochem. Med. Metab. Biol. 45 1991 154 160
58. M. Stancikova, Z. Lojda, J. Lukac, and M. Ruzickova Dipeptidyl peptidase IV in patients with systemic lupus erythematosus Clin. Exp. Rheumatol. 10 1992 381 385
59. M. Maes, I. De Meester, G. Vanhoof, S. Scharpe, E. Bosmans, C. Vandervorst, and et al. Decreased serum dipeptidyl peptidase IV activity in major depression Biol. Psychiatry 30 1991 577 586
60. S. Korom, I. De Meester, T.H. Stadlbauer, A. Chandraker, M. Schaub, M.H. Sayegh, and et al. Inhibition of CD26/dipeptidyl peptidase IV activity in vivo prolongs cardiac allograft survival in rat recipients Transplantation 63 1997 1495 1500
61. B. Bauvois, M. Djavaheri-Mergny, D. Rouillard, J. Dumont, and J. Wietzerbin Regulation of CD26/DPPIV gene expression by interferons and retinoic acid in tumor B cells Oncogene 19 2000 265 272
62. A. D'Angelo, O. Bluteau, M.A. Garcia-Gonzalez, L. Gresh, A. Doyen, S. Garbay, and et al. Hepatocyte nuclear factor 1alpha and beta control terminal differentiation and cell fate commitment in the gut epithelium Development 137 2010 1573 1582
63. R.H. Erickson, R.S. Lai, and Y.S. Kim Role of hepatocyte nuclear factor 1alpha and 1beta in the transcriptional regulation of human dipeptidyl peptidase IV during differentiation of Caco-2 cells Biochem. Biophys. Res. Commun. 270 2000 235 239
64. F.J. Salgado, E. Vela, M. Martin, R. Franco, M. Nogueira, and O.J. Cordero Mechanisms of CD26/dipeptidyl peptidase IV cytokine-dependent regulation on human activated lymphocytes Cytokine 12 2000 1136 1141
65. V. Stefanovic, N. Ardaillou, P. Vlahovic, S. Placier, P. Ronco, and R. Ardaillou Interferon-gamma induces dipeptidylpeptidase IV expression in human glomerular epithelial cells Immunology 80 1993 465 470
66. T. Yamabe, K. Takakura, K. Sugie, Y. Kitaoka, S. Takeda, Y. Okubo, and et al. Induction of the 2B9 antigen/dipeptidyl peptidase IV/CD26 on human natural killer cells by IL-2, IL-12 or IL-15 Immunology 91 1997 151 158
67. E. Nemoto, S. Sugawara, H. Takada, S. Shoji, and H. Horiuch Increase of CD26/dipeptidyl peptidase IV expression on human gingival fibroblasts upon stimulation with cytokines and bacterial components Infect. Immun. 67 1999 6225 6233
68. E.N. Arwert, R.A. Mentink, R.R. Driskell, E. Hoste, S.J. Goldie, S. Quist, and et al. Upregulation of CD26 expression in epithelial cells and stromal cells during wound-induced skin tumour formation Oncogene 31 8 2011 992 1000
69. H.E. Broxmeyer, J. Hoggatt, H.A. O'Leary, C. Mantel, B.R. Chitteti, S. Cooper, and et al. Dipeptidylpeptidase 4 negatively regulates colony-stimulating factor activity and stress hematopoiesis Nat. Med. 18 2012 1786 1796
70. C. Morimoto, Y. Torimoto, G. Levinson, C.E. Rudd, M. Schrieber, N.H. Dang, and et al. 1F7, a novel cell surface molecule, involved in helper function of CD4 cells J. Immunol. 143 1989 3430 3439
71. M. Martin, J. Huguet, J.J. Centelles, and R. Franco Expression of ecto-adenosine deaminase and CD26 in human T cells triggered by the TCR-CD3 complex. Possible role of adenosine deaminase as costimulatory molecule J. Immunol. 155 1995 4630 4643
72. N.H. Dang, Y. Torimoto, K. Sugita, J.F. Daley, P. Schow, C. Prado, and et al. Cell surface modulation of CD26 by anti-1F7 monoclonal antibody. Analysis of surface expression and human T cell activation J. Immunol. 145 1990 3963 3971
73. N.H. Dang, Y. Torimoto, K. Shimamura, T. Tanaka, J.F. Daley, S.F. Schlossman, and et al. 1F7 (CD26): a marker of thymic maturation involved in the differential regulation of the CD3 and CD2 pathways of human thymocyte activation J. Immunol. 147 1991 2825 2832
74. C. Morimoto, and S.F. Schlossman The structure and function of CD26 in the T-cell immune response Immunol. Rev. 161 1998 55 70
75. R. Pacheco, J.M. Martinez-Navio, M. Lejeune, N. Climent, H. Oliva, J.M. Gatell, and et al. CD26, adenosine deaminase, and adenosine receptors mediate costimulatory signals in the immunological synapse Proc. Natl. Acad. Sci. U. S. A. 102 2005 9583 9588
76. I.A. De Meester, L.L. Kestens, G.L. Vanham, G.C. Vanhoof, J.H. Vingerhoets, P.L. Gigase, and et al. Costimulation of CD4 + and CD8 + T cells through CD26: the ADA-binding epitope is not essential for complete signaling J. Leukoc. Biol. 58 1995 325 330
77. Y. Torimoto, N.H. Dang, E. Vivier, T. Tanaka, S.F. Schlossman, and C. Morimoto Coassociation of CD26 (dipeptidyl peptidase IV) with CD45 on the surface of human T lymphocytes J. Immunol. 147 1991 2514 2517
78. M. Hegen, J. Kameoka, R.P. Dong, S.F. Schlossman, and C. Morimoto Cross-linking of CD26 by antibody induces tyrosine phosphorylation and activation of mitogen-activated protein kinase Immunology 90 1997 257 264
79. D.M. Yu, L. Slaitini, V. Gysbers, A.G. Riekhoff, T. Kahne, H.M. Knott, and et al. Soluble CD26/dipeptidyl peptidase IV enhances human lymphocyte proliferation in vitro independent of dipeptidyl peptidase enzyme activity and adenosine deaminase binding Scand. J. Immunol. 73 2011 102 111
80. A. Barlan, J. Zhao, M.K. Sarkar, K. Li, P.B. McCray Jr., S. Perlman, and et al. Receptor variation and susceptibility to Middle East respiratory syndrome coronavirus infection J. Virol. 88 2014 4953 4961
81. G. Lu, Y. Hu, Q. Wang, J. Qi, F. Gao, Y. Li, and et al. Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26 Nature 500 2013 227 231
82. N. McIntyre, C.D. Holdsworth, and D.S. Turner New interpretation of oral glucose tolerance Lancet 2 1964 20 21
83. J. Plutzky The incretin axis in cardiovascular disease Circulation 124 2011 2285 2289
84. L.L. Baggio, and D.J. Drucker Biology of incretins: GLP-1 and GIP Gastroenterology 132 2007 2131 2157
85. S.J. Kim, K. Winter, C. Nian, M. Tsuneoka, Y. Koda, and C.H. McIntosh Glucose-dependent insulinotropic polypeptide (GIP) stimulation of pancreatic beta-cell survival is dependent upon phosphatidylinositol 3-kinase (PI3K)/protein kinase B (PKB) signaling, inactivation of the forkhead transcription factor Foxo1, and down-regulation of bax expression J. Biol. Chem. 280 2005 22297 22307
86. Y. Wang, C. Montrose-Rafizadeh, L. Adams, M. Raygada, O. Nadiv, and J.M. Egan GIP regulates glucose transporters, hexokinases, and glucose-induced insulin secretion in RIN 1046-38 cells Mol. Cell. Endocrinol. 116 1996 81 87
87. GGt Holz, W.M. Kuhtreiber, and J.F. Habener Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37) Nature 361 1993 362 365
88. J. Rachman, F.M. Gribble, B.A. Barrow, J.C. Levy, K.D. Buchanan, and R.C. Turner Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1 (7-36) amide in patients with NIDDM Diabetes 45 1996 1524 1530
89. M.A. Nauck, N. Kleine, C. Orskov, J.J. Holst, B. Willms, and W. Creutzfeldt Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients Diabetologia 36 1993 741 744
90. M. Zander, S. Madsbad, J.L. Madsen, and J.J. Holst Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study Lancet 359 2002 824 830
91. R.L. Prigeon, S. Quddusi, B. Paty, and D.A. D'Alessio Suppression of glucose production by GLP-1 independent of islet hormones: a novel extrapancreatic effect Am. J. Physiol. Endocrinol. Metab. 285 2003 E701 E707
92. H. Larsson, J.J. Holst, and B. Ahren Glucagon-like peptide-1 reduces hepatic glucose production indirectly through insulin and glucagon in humans Acta Physiol. Scand. 160 1997 413 422
93. J.G. Barrera, D.A. Sandoval, D.A. D'Alessio, and R.J. Seeley GLP-1 and energy balance: an integrated model of short-term and long-term control Nat. Rev. Endocrinol. 7 2011 507 516
94. C. Knauf, P.D. Cani, C. Perrin, M.A. Iglesias, J.F. Maury, E. Bernard, and et al. Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage J. Clin. Invest. 115 2005 3554 3563
95. J.R. Ussher, and D.J. Drucker Cardiovascular biology of the incretin system Endocr. Rev. 33 2012 187 215
96. E. Naslund, J. Bogefors, S. Skogar, P. Gryback, H. Jacobsson, J.J. Holst, and et al. GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans Am. J. Physiol. 277 1999 R910 R916
97. Y.S. Lee, M.S. Park, J.S. Choung, S.S. Kim, H.H. Oh, C.S. Choi, and et al. Glucagon-like peptide-1 inhibits adipose tissue macrophage infiltration and inflammation in an obese mouse model of diabetes Diabetologia 55 2012 2456 2468
98. T.D. Challa, N. Beaton, M. Arnold, G. Rudofsky, W. Langhans, and C. Wolfrum Regulation of adipocyte formation by GLP-1/GLP-1R signaling J. Biol. Chem. 287 2012 6421 6430
99. T.J. Kieffer, C.H. McIntosh, and R.A. Pederson Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV Endocrinology 136 1995 3585 3596
100. L. Pridal, C.F. Deacon, O. Kirk, J.V. Christensen, R.D. Carr, and J.J. Holst Glucagon-like peptide-1(7-37) has a larger volume of distribution than glucagon-like peptide-1(7-36)amide in dogs and is degraded more quickly in vitro by dog plasma Eur. J. Drug Metab. Pharmacokinet. 21 1996 51 59
101. R. Mentlein, B. Gallwitz, and W.E. Schmidt Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum Eur. J. Biochem. 214 1993 829 835
102. C.F. Deacon, A.H. Johnsen, and J.J. Holst Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo J. Clin. Endocrinol. Metab. 80 1995 952 957
103. R. Yazbeck, G.S. Howarth, and C.A. Abbott Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease? Trends Pharmacol. Sci. 30 2009 600 607
104. D.J. Drucker, and M.A. Nauck The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes Lancet 368 2006 1696 1705
105. I. Raz, M. Hanefeld, L. Xu, C. Caria, D. Williams-Herman, and H. Khatami Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus Diabetologia 49 2006 2564 2571
106. S.E. Inzucchi, and D.K. McGuire New drugs for the treatment of diabetes: part II: Incretin-based therapy and beyond Circulation 117 2008 574 584
107. A.M. Lambeir, S. Scharpe, and I. De Meester DPP4 inhibitors for diabetes - what next? Biochem. Pharmacol. 76 2008 1637 1643
108. T. Jose, and S.E. Inzucchi Cardiovascular effects of the DPP-4 inhibitors Diabetes Vasc. Dis. Res. 9 2012 109 116
109. H.M. Pattzi, S. Pitale, M. Alpizar, C. Bennett, A.M. O'Farrell, J. Li, and et al. Dutogliptin, a selective DPP4 inhibitor, improves glycaemic control in patients with type 2 diabetes: a 12-week, double-blind, randomized, placebo-controlled, multicentre trial Diabetes Obes. Metab. 12 2010 348 355
110. G.S. Hotamisligil Inflammation and metabolic disorders Nature 444 2006 860 867
111. J.P. Despres, and I. Lemieux Abdominal obesity and metabolic syndrome Nature 444 2006 881 887
112. T. Horng, and G.S. Hotamisligil Linking the inflammasome to obesity-related disease Nat. Med. 17 2011 164 165
113. M. Feuerer, L. Herrero, D. Cipolletta, A. Naaz, J. Wong, A. Nayer, and et al. Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters Nat. Med. 15 2009 930 939
114. S. Nishimura, I. Manabe, M. Nagasaki, K. Eto, H. Yamashita, M. Ohsugi, and et al. CD8 + effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity Nat. Med. 15 2009 914 920
115. H. Sell, C. Habich, and J. Eckel Adaptive immunity in obesity and insulin resistance Nat. Rev. Endocrinol. 8 2012 709 716
116. S. Deaglio, K.M. Dwyer, W. Gao, D. Friedman, A. Usheva, A. Erat, and et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression J. Exp. Med. 204 2007 1257 1265
117. R. Resta, Y. Yamashita, and L.F. Thompson Ecto-enzyme and signaling functions of lymphocyte CD73 Immunol. Rev. 161 1998 95 109
118. M.S. Hershfield New insights into adenosine-receptor-mediated immunosuppression and the role of adenosine in causing the immunodeficiency associated with adenosine deaminase deficiency Eur. J. Immunol. 35 2005 25 30
119. A. Mortellaro, R.J. Hernandez, M.M. Guerrini, F. Carlucci, A. Tabucchi, M. Ponzoni, and et al. Ex vivo gene therapy with lentiviral vectors rescues adenosine deaminase (ADA)-deficient mice and corrects their immune and metabolic defects Blood 108 2006 2979 2988
120. J.J. Sanchez, G. Monaghan, C. Borsting, G. Norbury, N. Morling, and H.B. Gaspar Carrier frequency of a nonsense mutation in the adenosine deaminase (ADA) gene implies a high incidence of ADA-deficient severe combined immunodeficiency (SCID) in Somalia and a single, common haplotype indicates common ancestry Ann. Hum. Genet. 71 2007 336 347
121. R.P. Dong, K. Tachibana, M. Hegen, Y. Munakata, D. Cho, S.F. Schlossman, and et al. Determination of adenosine deaminase binding domain on CD26 and its immunoregulatory effect on T cell activation J. Immunol. 159 1997 6070 6076
122. R. Franco, R. Pacheco, J.M. Gatell, T. Gallart, and C. Lluis Enzymatic and extraenzymatic role of adenosine deaminase 1 in T-cell-dendritic cell contacts and in alterations of the immune function Crit. Rev. Immunol. 27 2007 495 509
123. A.V. Zavialov, E. Gracia, N. Glaichenhaus, R. Franco, and G. Lauvau Human adenosine deaminase 2 induces differentiation of monocytes into macrophages and stimulates proliferation of T helper cells and macrophages J. Leukoc. Biol. 88 2010 279 290
124. A.V. Zavialov, and A. Engstrom Human ADA2 belongs to a new family of growth factors with adenosine deaminase activity Biochem. J. 391 2005 51 57
125. K. Ohnuma, Y. Munakata, T. Ishii, S. Iwata, S. Kobayashi, O. Hosono, and et al. Soluble CD26/dipeptidyl peptidase IV induces T cell proliferation through CD86 up-regulation on APCs J. Immunol. 167 2001 6745 6755
126. K. Ohnuma, T. Yamochi, M. Uchiyama, K. Nishibashi, N. Yoshikawa, N. Shimizu, and et al. CD26 up-regulates expression of CD86 on antigen-presenting cells by means of caveolin-1 Proc. Natl. Acad. Sci. U. S. A. 101 2004 14186 14191
127. K. Ohnuma, N. Takahashi, T. Yamochi, O. Hosono, N.H. Dang, and C. Morimoto Role of CD26/dipeptidyl peptidase IV in human T cell activation and function Front. Biosci. 13 2008 2299 2310
128. K. Ohnuma, T. Yamochi, M. Uchiyama, K. Nishibashi, S. Iwata, O. Hosono, and et al. CD26 mediates dissociation of Tollip and IRAK-1 from caveolin-1 and induces upregulation of CD86 on antigen-presenting cells Mol. Cell. Biol. 25 2005 7743 7757
129. K. Ohnuma, H. Inoue, M. Uchiyama, T. Yamochi, O. Hosono, N.H. Dang, and et al. T-cell activation via CD26 and caveolin-1 in rheumatoid synovium Mod. Rheumatol. 16 2006 3 13
130. K. Loster, K. Zeilinger, D. Schuppan, and W. Reutter The cysteine-rich region of dipeptidyl peptidase IV (CD 26) is the collagen-binding site Biochem. Biophys. Res. Commun. 217 1995 341 348
131. B.P. Bullock, R.S. Heller, and J.F. Habener Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor Endocrinology 137 1996 2968 2978
132. K.E. Mayo, L.J. Miller, D. Bataille, S. Dalle, B. Goke, B. Thorens, and et al. International Union of Pharmacology. XXXV. The glucagon receptor family Pharmacol. Rev. 55 2003 167 194
133. B. Thorens Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1 Proc. Natl. Acad. Sci. U. S. A. 89 1992 8641 8645
134. T. Kitamura, J. Nakae, Y. Kitamura, Y. Kido, W.H. Biggs III, C.V. Wright, and et al. The forkhead transcription factor Foxo1 links insulin signaling to Pdx1 regulation of pancreatic beta cell growth J. Clin. Invest. 110 2002 1839 1847
135. J. Buteau, M.L. Spatz, and D. Accili Transcription factor FoxO1 mediates glucagon-like peptide-1 effects on pancreatic beta-cell mass Diabetes 55 2006 1190 1196
136. H. Hui, A. Nourparvar, X. Zhao, and R. Perfetti Glucagon-like peptide-1 inhibits apoptosis of insulin-secreting cells via a cyclic 5′-adenosine monophosphate-dependent protein kinase A- and a phosphatidylinositol 3-kinase-dependent pathway Endocrinology 144 2003 1444 1455
137. T. Nystrom, M.K. Gutniak, Q. Zhang, F. Zhang, J.J. Holst, B. Ahren, and et al. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease Am. J. Physiol. Endocrinol. Metab. 287 2004 E1209 E1215
138. A. Ceriello, K. Esposito, R. Testa, A.R. Bonfigli, M. Marra, and D. Giugliano The possible protective role of glucagon-like peptide 1 on endothelium during the meal and evidence for an "endothelial resistance" to glucagon-like peptide 1 in diabetes Diabetes Care 34 2011 697 702
139. O. Erdogdu, D. Nathanson, A. Sjoholm, T. Nystrom, and Q. Zhang Exendin-4 stimulates proliferation of human coronary artery endothelial cells through eNOS-, PKA- and PI3K/Akt-dependent pathways and requires GLP-1 receptor Mol. Cell. Endocrinol. 325 2010 26 35
140. C.Y. Huang, C.M. Shih, N.W. Tsao, Y.W. Lin, P.H. Huang, S.C. Wu, and et al. Dipeptidyl peptidase-4 inhibitor improves neovascularization by increasing circulating endothelial progenitor cells Br. J. Pharmacol. 167 2012 1506 1519
141. X. Xiao-Yun, M. Zhao-Hui, C. Ke, H. Hong-Hui, and X. Yan-Hong Glucagon-like peptide-1 improves proliferation and differentiation of endothelial progenitor cells via upregulating VEGF generation Med. Sci. Monit. 17 2011 BR35 BR41
142. K. Ban, M.H. Noyan-Ashraf, J. Hoefer, S.S. Bolz, D.J. Drucker, and M. Husain Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways Circulation 117 2008 2340 2350
143. Y. Hattori, T. Jojima, A. Tomizawa, H. Satoh, S. Hattori, K. Kasai, and et al. A glucagon-like peptide-1 (GLP-1) analogue, liraglutide, upregulates nitric oxide production and exerts anti-inflammatory action in endothelial cells Diabetologia 53 2010 2256 2263
144. Z. Shah, C. Pineda, T. Kampfrath, A. Maiseyeu, Z. Ying, I. Racoma, and et al. Acute DPP-4 inhibition modulates vascular tone through GLP-1 independent pathways Vasc. Pharmacol. 55 2011 2 9
145. G.P. Fadini, E. Boscaro, M. Albiero, L. Menegazzo, V. Frison, S. de Kreutzenberg, and et al. The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha Diabetes Care 33 2010 1607 1609
146. B. Hocher, Y. Sharkovska, M. Mark, T. Klein, and T. Pfab The novel DPP-4 inhibitors linagliptin and BI 14361 reduce infarct size after myocardial ischemia/reperfusion in rats Int. J. Cardiol. 167 2013 87 93
147. K.W. Christopherson II, G. Hangoc, C.R. Mantel, and H.E. Broxmeyer Modulation of hematopoietic stem cell homing and engraftment by CD26 Science 305 2004 1000 1003
148. K.W. Christopherson II, L.A. Paganessi, S. Napier, and N.K. Porecha CD26 inhibition on CD34 + or lineage- human umbilical cord blood donor hematopoietic stem cells/hematopoietic progenitor cells improves long-term engraftment into NOD/SCID/Beta2null immunodeficient mice Stem Cells Dev. 16 2007 355 360
149. K.W. Christopherson II, G. Hangoc, and H.E. Broxmeyer Cell surface peptidase CD26/dipeptidylpeptidase IV regulates CXCL12/stromal cell-derived factor-1 alpha-mediated chemotaxis of human cord blood CD34 + progenitor cells J. Immunol. 169 2002 7000 7008
150. A. Peled, I. Petit, O. Kollet, M. Magid, T. Ponomaryov, T. Byk, and et al. Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4 Science 283 1999 845 848
151. G. Ghersi, W. Chen, E.W. Lee, and Z. Zukowska Critical role of dipeptidyl peptidase IV in neuropeptide Y-mediated endothelial cell migration in response to wounding Peptides 22 2001 453 458
152. K.D. Olinde, and J.B. O'Connell Inflammatory heart disease: pathogenesis, clinical manifestations, and treatment of myocarditis Annu. Rev. Med. 45 1994 481 490
153. E. Schon, S. Jahn, S.T. Kiessig, H.U. Demuth, K. Neubert, A. Barth, and et al. The role of dipeptidyl peptidase IV in human T lymphocyte activation. Inhibitors and antibodies against dipeptidyl peptidase IV suppress lymphocyte proliferation and immunoglobulin synthesis in vitro Eur. J. Immunol. 17 1987 1821 1826
154. G.R. Flentke, E. Munoz, B.T. Huber, A.G. Plaut, C.A. Kettner, and W.W. Bachovchin Inhibition of dipeptidyl aminopeptidase IV (DP-IV) by Xaa-boroPro dipeptides and use of these inhibitors to examine the role of DP-IV in T-cell function Proc. Natl. Acad. Sci. U. S. A. 88 1991 1556 1559
155. D. Reinhold, U. Bank, F. Buhling, U. Lendeckel, J. Faust, K. Neubert, and et al. Inhibitors of dipeptidyl peptidase IV induce secretion of transforming growth factor-beta 1 in PWM-stimulated PBMC and T cells Immunology 91 1997 354 360
156. D. Reinhold, U. Bank, F. Buhling, K. Neubert, T. Mattern, A.J. Ulmer, and et al. Dipeptidyl peptidase IV (CD26) on human lymphocytes. Synthetic inhibitors of and antibodies against dipeptidyl peptidase IV suppress the proliferation of pokeweed mitogen-stimulated peripheral blood mononuclear cells, and IL-2 and IL-6 production Immunobiology 188 1993 403 414
157. D. Reinhold, U. Bank, F. Buhling, M. Tager, I. Born, J. Faust, and et al. Inhibitors of dipeptidyl peptidase IV (DP IV, CD26) induces secretion of transforming growth factor-beta 1 (TGF-beta 1) in stimulated mouse splenocytes and thymocytes Immunol. Lett. 58 1997 29 35
158. T. Kahne, U. Lendeckel, S. Wrenger, K. Neubert, S. Ansorge, and D. Reinhold Dipeptidyl peptidase IV: a cell surface peptidase involved in regulating T cell growth (review) Int. J. Mol. Med. 4 1999 3 15
159. T. Tanaka, J. Kameoka, A. Yaron, S.F. Schlossman, and C. Morimoto The costimulatory activity of the CD26 antigen requires dipeptidyl peptidase IV enzymatic activity Proc. Natl. Acad. Sci. U. S. A. 90 1993 4586 4590
160. T. Tanaka, J.S. Duke-Cohan, J. Kameoka, A. Yaron, I. Lee, S.F. Schlossman, and et al. Enhancement of antigen-induced T-cell proliferation by soluble CD26/dipeptidyl peptidase IV Proc. Natl. Acad. Sci. U. S. A. 91 1994 3082 3086
161. B. Fleischer, E. Sturm, J.E. De Vries, and H. Spits Triggering of cytotoxic T lymphocytes and NK cells via the Tp103 pathway is dependent on the expression of the T cell receptor/CD3 complex J. Immunol. 141 1988 1103 1107
162. H.W. Mittrucker, C. Steeg, B. Malissen, and B. Fleischer The cytoplasmic tail of the T cell receptor zeta chain is required for signaling via CD26 Eur. J. Immunol. 25 1995 295 297
163. N.H. Dang, and C. Morimoto CD26: an expanding role in immune regulation and cancer Histol. Histopathol. 17 2002 1213 1226